Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103308 | 0.75 | CCNT1 (0.42) | ESR2TLR9TLR7TLR8CCNT1 | |
| SCHEMBL17731023 | 0.74 | CDK5 (0.40) | CSNK2A2CSNK2A1TLR9TLR7TLR8 | |
| SCHEMBL18180513 | 0.73 | ESR2 (0.45) | ESR2CCNT1CDK9 | |
| SCHEMBL20103404 | 0.70 | ESR1 (0.46) | ESR2CSNK2A2CSNK2A1TLR9TLR7 | |
| SCHEMBL20524227 | 0.70 | ESR2 (1.00) | ESR2 | |
| SCHEMBL16116782 | 0.68 | LOX (0.55) | LOXLOXL2ACVR2ATGFBR1TGFBR2 | |
| SCHEMBL30626327 | 0.68 | LOX (0.55) | LOXLOXL2ACVR2ATGFBR1TGFBR2 | |
| SCHEMBL21381369 | 0.68 | CCNT1 (0.41) | ESR2TLR9TLR7TLR8CCNT1 | |
| SCHEMBL30790744 | 0.67 | SMARCA2 (0.45) | — | |
| SCHEMBL20103431 | 0.67 | ESR2 (0.46) | ESR2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | ESR2 97/4885CSNK2A2 1176/4885CSNK2A1 1596/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | ESR2 97/4885CSNK2A2 1176/4885CSNK2A1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.